Nav: Home

Human antiviral 'GS-441524' shows great promise against this infectious disease of cats

February 13, 2019

The emergence of exotic diseases such as Ebola and SARS (severe acute respiratory syndrome) in people has prompted intensive research into new drug treatments, and this is indirectly bringing benefit to cats. Feline infectious peritonitis (FIP) is one of a number of chronic viral infections of cats that resemble those in people, and is estimated to kill up to 1.4% of cats around the world. The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.

Among the most promising treatments against emerging viruses in humans is 'GS-5734', one of the small-molecule antivirals targeting specific proteins involved in RNA virus replication. In studies, it has proven effective in preventing Ebola in rhesus monkeys and inhibiting coronaviruses both in tissue culture and in mouse infection models. It was these findings that brought it to the attention of a team of veterinary researchers in the USA, led by Professor Niels Pedersen of the University of California, Davis. Their own initial studies involving experimental FIP showed that the less chemically complex 'GS-441524', the parent nucleoside of GS-5734, was highly effective, opening the way for a field trial in cats with naturally occurring FIP. The results have been striking, and were published in the Journal of Feline Medicine and Surgery (JFMS) on 13 February 2019.*

Thirty-one cats, ranging in age from 3-73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanized due to their severe disease. For these 26 cats, the clinical response was dramatic: fever usually resolved within 12-36 h, concurrent with a marked improvement in appetite, activity levels and weight gain. In cats with the more common effusive or 'wet' form of FIP, abdominal effusions rapidly disappeared, starting at around 10-14 days after commencing treatment. Encouragingly, and somewhat unexpectedly, cats with non-effusive ('dry') FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.

Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.

Previously the prospects for cats with FIP were bleak. In a seminal review paper on FIP published in JFMS a decade ago, Professor Pedersen stated: 'no treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of their disease in days, weeks or months.'1 Now, as he approaches the end of his professional career, Professor Pedersen is considerably more optimistic: 'FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP.' However, he cautions: 'It must be emphasized that the field trial we report was for proof-of-concept and the results cannot be immediately translated into commercially available products. Unfortunately, the real hope provided by these initial trials has increased, and not decreased, the desperation of owners to seek out these new drugs on the black market. As eventful as these discoveries may be, there is still much more about FIP to discover. I would like to thank all of the people, organizations and owners who have assisted in my research over this half century and leave remaining questions and associated discoveries for my fellow FIP researchers.'
-end-
Reference

1 Pedersen NC. Review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 2009; 11: 225-258.

*Pedersen NC, Perron M, Bannasch M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. Epub ahead of print 13 February 2019. DOI: 10.1177/1098612X19825701. This article is free to read here.

Picture: Bubba, one of the study cats, who had been found as an abandoned 3-week-old kitten by his owner in Florida, USA. At the age of 7, having been diagnosed with abdominal non-effusive FIP, he was enrolled in the GS-441524 treatment study. (a) Bubba pictured in May 2017, just before treatment commenced; he was sick and anorexic, weighing 6 kg (13.5 lb). One week into the 12-week treatment course his owner reported he was 'eating on his own, alert, energetic and playful.' (b) Bubba, pictured in January 2018, weighing 9.3 kg (20.5 lb). Credit: Adel Gastle

About the Journal of Feline Medicine and Surgery

The Journal of Feline Medicine and Surgery (jfms.com) is the official journal of the International Society of Feline Medicine (ISFM) and the American Association of Feline Practitioners (AAFP), and is published by SAGE Publishing.

SAGE

Related Ebola Articles:

Ebola survivors have a 'unique' retinal scar
Researchers from the University of Liverpool have conducted a study of Ebola survivors to determine if the virus has any specific effects on the back on the eye using an ultra widefield retinal camera.
Ebola: Lives to be saved with new management approach
Ebola outbreaks are set to be managed quickly and efficiently -- saving lives -- with a new approach developed by an international team of researchers, including the University of Warwick, which helps to streamline outbreak decision-making.
Ebola vaccines provide immune responses after 1 year
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
New scoring system predicts Ebola severity
While Ebola virus disease (EVD) is notorious for being one of the world's most deadly infections, it actually has a wide range of outcomes, where asymptomatic presentation may be as common as fatality.
Could co-infection with other viruses affect the survival of those with Ebola virus?
Could co-infection with other viruses have a detrimental affect on Ebola survival, and why did some show Ebola symptoms without having the virus?
Antimalarial being tested as possible Ebola virus drug
The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc.
Ebola map may help prepare for future outbreaks
To be prepared for new Ebola virus disease cases, it is fundamental to start by identifying the range of the virus and the regions that are more favorable for its propagation.
Sexual transmission of Ebola likely to impact course of outbreaks
Sexual transmission of the Ebola virus could have a major impact on the dynamics of the disease, potentially reigniting an outbreak that has been contained by public health interventions, according to research by University of Georgia ecologists just published in the Royal Society journal Biology Letters.
Ebola vaccine: Promising phase I trials
The clinical phase I trial of a potential vaccine against the dreaded Ebola virus has been successfully completed at four partner sites in Africa and Europe.
Improving treatments for post-Ebola syndrome sufferers
Researchers from the University of Liverpool and the King's Sierra Leone Partnership are to present new findings into post-Ebola syndrome at a major European conference this week.

Related Ebola Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".